Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore

Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021

Skanray to raise Rs 400 crore to fund its inorganic growth

Since its inception, the company has either acquired or taken a majority stake in five companies

Everest Organics develops API for molnupiravir

The drug is being developed at lab scale for the first-line of treatment of Covid-19

Ami Organics bets on strategic acquisitions as its IPO opens on Sept 1

The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio

Everest Organics launches 'Posaconazole' API

Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients

Lonza to sell capsules & health ingredients business for $3 billion in major strategic shift

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results

Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY

The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore

Zydus Lifesciences reports strong Q3 & 9M FY26 growth

Revenue from operations surged 30% year-on-year to Rs. 68,645 million

Revvity posts higher Q4 earnings, lifts 2026 outlook as diagnostics strength offsets margin pressure

Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come